CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

BrequinarWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug2782 community health worker support Wiki 1.00
drug2774 care as usual Wiki 1.00
drug2319 Standard of Care Wiki 0.20

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 The CRISIS Study: A Randomized Open-label Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Hospitalized Adults With Coronavirus-19 (COVID-19)

This will be a phase 1a randomized, open label, multi-center study with approximately 24 subjects. All subjects will receive standard of care (SOC) per institutional guidelines for treatment of hospitalized patients with COVID-19 infection. In addition to SOC, the brequinar group will receive 5 daily doses of brequinar 100 mg.

NCT04425252 COVID-19 Drug: Brequinar Other: Standard of Care
MeSH:Coronavirus Infections

Primary Outcomes

Description: Adverse events are new onset medical conditions.

Measure: Safety/tolerability measured by rates of post randomization adverse events and hematology/chemistry safety labs.

Time: Beginning at signing consent through Day 15.

Secondary Outcomes

Description: In-patient hospitalization, hospitalized in ICU-level care, or discharged

Measure: Hospitalization status

Time: Through Day 15

Description: Duration in days from admission to discharge

Measure: Duration of hospitalization

Time: Through Day 15

Description: National Early Warning Score (NEWS) 2. Composite score of respiration rate, oxygen saturation, systolic blood pressure, pulse, consciousness, and temperature.

Measure: NEWS2 Score

Time: Through Day 15

Description: Subject mortality status

Measure: Mortality

Time: Day 29

Description: Nasopharyngeal viral load by RT-PCR at days 1, 3, 5, 7, and 15

Measure: SARS-CoV-2 nasopharyngeal viral load

Time: Through Day 15

Description: Pro-inflammatory cytokines including TNFalpha, INFgamma, IL13, IL12p70, IL10, IL8, IL6, IL4 IL2, IL1-beta and erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), D-dimer, serum ferritin, and fibrinogen

Measure: Inflammatory markers

Time: Through Day 15

Description: Plasma concentration of dihydroorotate

Measure: DHO Concentration

Time: Through Day 15

Description: Plasma concentration of brequinar

Measure: Brequinar Concentration

Time: Through Day 15

No related HPO nodes (Using clinical trials)